1. Home
  2. EH vs CCCC Comparison

EH vs CCCC Comparison

Compare EH & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo EHang Holdings Limited ADS

EH

EHang Holdings Limited ADS

SELL

Current Price

$3.65

Market Cap

314.0M

Sector

Industrials

ML Signal

SELL

Logo C4 Therapeutics Inc.

CCCC

C4 Therapeutics Inc.

HOLD

Current Price

$3.28

Market Cap

350.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EH
CCCC
Founded
2014
2015
Country
China
United States
Employees
N/A
N/A
Industry
Military/Government/Technical
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
314.0M
350.6M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
EH
CCCC
Price
$3.65
$3.28
Analyst Decision
Buy
Strong Buy
Analyst Count
10
8
Target Price
$7.85
★ $12.86
AVG Volume (30 Days)
675.9K
★ 2.7M
Earning Date
11-25-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 16.45
EPS
★ N/A
N/A
Revenue
N/A
★ $35,947,000.00
Revenue This Year
$1.85
N/A
Revenue Next Year
$70.64
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 1.02
52 Week Low
$3.31
$1.69
52 Week High
$18.65
$5.17

Technical Indicators

Market Signals
Indicator
EH
CCCC
Relative Strength Index (RSI) 38.51 54.59
Support Level N/A $2.55
Resistance Level $4.84 $3.91
Average True Range (ATR) 0.20 0.21
MACD 0.03 0.07
Stochastic Oscillator 38.98 73.94

Price Performance

Historical Comparison
EH
CCCC

About EH EHang Holdings Limited ADS

EHang Holdings Ltd is an urban air mobility (UAM) technology platform company focused on autonomous aerial vehicle technology and solutions. The company provides unmanned aerial vehicle (UAV) systems and solutions for air mobility, including passenger transportation and logistics, as well as smart city management and aerial media solutions. Its EH216-S passenger-carrying pilotless eVTOL aircraft has obtained a production certificate and standard airworthiness certificate from the Civil Aviation Administration of China (CAAC).

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.

Share on Social Networks: